The Prognostic Role of [18F]FDG PET/CT in Patients with Advanced Cutaneous Squamous Cell Carcinoma Submitted to Cemiplimab Immunotherapy: A Single-Center Retrospective Study
Published 2023 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
The Prognostic Role of [18F]FDG PET/CT in Patients with Advanced Cutaneous Squamous Cell Carcinoma Submitted to Cemiplimab Immunotherapy: A Single-Center Retrospective Study
Authors
Keywords
-
Journal
CANCER BIOTHERAPY AND RADIOPHARMACEUTICALS
Volume -, Issue -, Pages -
Publisher
Mary Ann Liebert Inc
Online
2023-10-27
DOI
10.1089/cbr.2023.0110
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Novelties from the Joint EANM/SNMMI/ANZSNM Guidelines on Immunotherapy
- (2023) Egesta Lopci et al. CANCER BIOTHERAPY AND RADIOPHARMACEUTICALS
- Real-Life Study of the Benefit of Concomitant Radiotherapy with Cemiplimab in Advanced Cutaneous Squamous Cell Carcinoma (cSCC): A Retrospective Cohort Study
- (2023) Barbara Bailly-Caillé et al. Cancers
- ITA-IMMUNO-PET: The Role of [18F]FDG PET/CT for Assessing Response to Immunotherapy in Patients with Some Solid Tumors
- (2023) Laura Evangelista et al. Cancers
- Immunotherapy for Cancer: Something Old, Something New
- (2023) Luca Filippi et al. CANCER BIOTHERAPY AND RADIOPHARMACEUTICALS
- IL-6 as new prognostic factor in patients with advanced cutaneous squamous cell carcinoma treated with cemiplimab
- (2023) Domenico Mallardo et al. Journal of Translational Medicine
- The value on SUV-derived parameters assessed on 18F-FDG PET/CT for predicting mediastinal lymph node metastasis in non-small cell lung cancer
- (2023) Xuhe Liao et al. BMC MEDICAL IMAGING
- Prognostic value of inflammatory markers and clinical features for survival in advanced or metastatic esophageal squamous cell carcinoma patients receiving anti-programmed death 1 treatment
- (2023) Liangshan Da et al. Frontiers in Oncology
- Cutaneous Squamous Cell Carcinoma Subjected to Anti PD-1 Immunotherapy: Monitoring Response Through Serial PET/CT Scans with 18F-FDG
- (2022) Luca Filippi et al. CANCER BIOTHERAPY AND RADIOPHARMACEUTICALS
- Assessing dynamic metabolic heterogeneity in non-small cell lung cancer patients via ultra-high sensitivity total-body [18F]FDG PET/CT imaging: quantitative analysis of [18F]FDG uptake in primary tumors and metastatic lymph nodes
- (2022) DaQuan Wang et al. EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING
- Long axial field-of-view PET/CT devices: are we ready for the technological revolution?
- (2022) Luca Filippi et al. Expert Review of Medical Devices
- Neoadjuvant Cemiplimab for Stage II to IV Cutaneous Squamous-Cell Carcinoma
- (2022) Neil D. Gross et al. NEW ENGLAND JOURNAL OF MEDICINE
- Emerging and Evolving Concepts in Cancer Immunotherapy Imaging
- (2022) Laurent Dercle et al. RADIOLOGY
- Predictive Value of Baseline FDG-PET/CT for the Durable Response to Immune Checkpoint Inhibition in NSCLC Patients Using the Morphological and Metabolic Features of Primary Tumors
- (2022) Ken Kudura et al. Cancers
- Rationale for LDH-targeted cancer immunotherapy
- (2022) Tina B.S. Miholjcic et al. EUROPEAN JOURNAL OF CANCER
- Failure of Immunotherapy—The Molecular and Immunological Origin of Immunotherapy Resistance in Lung Cancer
- (2021) Justyna Błach et al. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
- Assessment of early metabolic progression in melanoma patients under immunotherapy: an 18F-FDG PET/CT study
- (2021) Christos Sachpekidis et al. EJNMMI Research
- Therapeutic Advancements Across Clinical Stages in Melanoma, With a Focus on Targeted Immunotherapy
- (2021) Claudia Trojaniello et al. Frontiers in Oncology
- FDG-PET/CT imaging for evaluating durable responses to immune check point inhibitors in patients with advanced cutaneous squamous cell carcinoma
- (2021) Luke S. McLean et al. CANCER IMAGING
- Cemiplimab in locally advanced cutaneous squamous cell carcinoma: results from an open-label, phase 2, single-arm trial
- (2020) Michael R Migden et al. LANCET ONCOLOGY
- Atezolizumab plus Bevacizumab in Unresectable Hepatocellular Carcinoma
- (2020) Richard S. Finn et al. NEW ENGLAND JOURNAL OF MEDICINE
- 18F-FDG PET/CT based spleen to liver ratio associates with clinical outcome to ipilimumab in patients with metastatic melanoma
- (2020) Annie Wong et al. CANCER IMAGING
- Surrogate endpoints for overall survival in randomised controlled trials of localised osteosarcoma: A meta-analytic evaluation
- (2020) Kazuhiro Tanaka et al. Scientific Reports
- PD-L1 expression correlation with metabolic parameters of FDG PET/CT and clinicopathological characteristics in non-small cell lung cancer
- (2020) Xiaodong Wu et al. EJNMMI Research
- Molecular imaging in immuno-oncology: current status and translational perspectives
- (2020) Luca Filippi et al. EXPERT REVIEW OF MOLECULAR DIAGNOSTICS
- Monitoring anti-PD-1-based immunotherapy in non-small cell lung cancer with FDG PET: introduction of iPERCIST
- (2019) Lucas Goldfarb et al. EJNMMI Research
- 18F-FDG PET/CT in non-small-cell lung cancer patients
- (2019) Laura Evangelista et al. NUCLEAR MEDICINE COMMUNICATIONS
- Absolute number of new lesions on 18F-FDG PET/CT is more predictive of clinical response than SUV changes in metastatic melanoma patients receiving ipilimumab
- (2017) Hoda Anwar et al. EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING
- FDG PET/CT: EANM procedure guidelines for tumour imaging: version 2.0
- (2014) Ronald Boellaard et al. EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING
- Predictive value of early 18F-FDG PET/CT studies for treatment response evaluation to ipilimumab in metastatic melanoma: preliminary results of an ongoing study
- (2014) Christos Sachpekidis et al. EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING
- Independent prognostic value of whole-body metabolic tumor burden from FDG-PET in non-small cell lung cancer
- (2012) Hao Zhang et al. International Journal of Computer Assisted Radiology and Surgery
- 18F-FDG PET After 2 Cycles of ABVD Predicts Event-Free Survival in Early and Advanced Hodgkin Lymphoma
- (2010) J. J. Cerci et al. JOURNAL OF NUCLEAR MEDICINE
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreDiscover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversation